Methofill Sd (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This limits the proliferation of rapidly dividing cells, such as immune cells involved in autoimmunity and cancer cells, while also promoting anti‑inflammatory pathways through increased adenosine release.

The specific dose and dosing schedule of Methofill Sd are determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment response. Healthcare providers set the appropriate regimen and adjust it as needed during therapy.

Methofill Sd is classified as pregnancy category X because it is highly teratogenic and can cause fetal harm. It should not be used by pregnant women. Breastfeeding is also contraindicated, as methotrexate is excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Methofill Sd (methotrexate) is often considered a first‑line DMARD because of its proven efficacy, oral or injectable formulations, and cost‑effectiveness. Compared with biologic agents, methotrexate has a broader safety profile but may require more laboratory monitoring. Choice of therapy depends on disease severity, patient comorbidities and treatment goals.

Methofill Sd should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Methofill Sd is supplied as a sterile solution for subcutaneous injection. The injection is typically given by a healthcare professional or trained patient using a pre‑filled syringe or needle‑free device, following aseptic technique. Injection sites are rotated to minimize local irritation.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to anemia or infection, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored regularly for liver enzymes, blood counts and respiratory symptoms, and any alarming signs should prompt immediate medical evaluation.

Methofill Sd is contraindicated in pregnant women, breastfeeding mothers, patients with severe renal or hepatic impairment, and individuals with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with active infections or pre‑existing lung disease.